Combination therapy is the standard of care

Cutis

Volumn 76, Issue 2 SUPPL., 2005, Pages 8-14

  Tanghetti, Emil A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

^c Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ISOTRETINOIN; KERATOLYTIC AGENT; RETINOID;

ACNE VULGARIS; ARTICLE; DRUG COMBINATION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SEBUM; TREATMENT OUTCOME;

ACNE VULGARIS; ANDROGEN ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; RETINOIDS; SEBUM; TREATMENT OUTCOME;

EID: 24744439723     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9:179-187.
2. Liao DC. Management of acne. J Fam Pract. 2003;52:43-51.
3. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):S200-S210.
4. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726-735.
5. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49:S1-S37.
6. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(suppl 4):2-15.
7. Johnson BA, Nunley JR. Topical therapy for acne vulgaris. how do you choose the best drug for each patient? Postgrad Med. 2000;107:69-80.
8. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997;336:1156-1162.
9. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49:S227-S232.
10. Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61:357-366.
11. Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med. 2001;68:279-286.
12. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(suppl 52):48-56.
13. Leyden JL, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69(suppl 2):12-19.
14. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(suppl 6):4-9.
15. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(suppl 2):4-11.
16. Eady EA, Cove JH, Joanes DN, et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat. 1990;1:215-226.
17. Oh CW, Myung KB. An ultrastructural study of the retention hyperkeratosis of experimentally induced comedones in rabbits: the effects of three comedolytics. J Dermatol. 1996;23:169-180.
18. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.
19. Fagundes DS, Fraser JM, Klauda HC. Difference in the irritation potential and cosmetic acceptability of two combination topical acne gels - combined results of two comparative studies. Today's Ther Trends. 2003;21:269-275.
20. Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effects in vivo of minocycline, doxycycline, and tetracycline in humans. J Dermatol Treat. 1996;7:223-225.
21. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on chemotaxis. J Invest Dermatol. 1978;70:51-55.
22. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol. 1981;104:453-457.
23. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
24. Gammon WR, Meyer C, Lantis S, et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. a double-blind study. J Am Acad Dermatol. 1986;14:183-186.
25. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;(1):CD002086.
26. Eady EA, Cove JH, Holland KT, et al. Erythromycin-resistant Propionibacteria in antibiotic-treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121:51-57.
27. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.
28. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant Propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993;128:556-560.
29. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis. 2004;73(suppl 6):6-10.
30. Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol. 1983;9:933-936.
31. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis. 2001;67(suppl 2):21-24.
32. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol. 1994;131:331-336.
33. Pfeiffer N. Drug combination trumps single-agent acne treatment. Derm Times. 2005;26:26-27.
34. Tanghetti E, Gold M, Fraser J. A two-center patient preference study comparing two acne gels. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P108.
35. Shalita A, Tanghetti E, Abramovits W, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized, parallel-group trial. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P147.
36. Bikowski J. Case study results of clindamycin 1%/benzoyl peroxide 5% topical gel for monotherapy and in combination acne treatment. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P118.
37. Martin B, Meunier C, Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(suppl 52):8-11.